Teva Pharmaceutical Industries Other Non-Cash Items 2010-2024 | TEVA
Teva Pharmaceutical Industries annual/quarterly other non-cash items history and growth rate from 2010 to 2024. Other non-cash items can be defined as miscellaneous non-cash adjustments to Net income.
- Teva Pharmaceutical Industries other non-cash items for the quarter ending December 31, 2024 were $2.582B, a 186.25% increase year-over-year.
- Teva Pharmaceutical Industries other non-cash items for the twelve months ending December 31, 2024 were $6.107B, a 128.81% increase year-over-year.
- Teva Pharmaceutical Industries annual other non-cash items for 2024 were $2.582B, a 186.25% increase from 2023.
- Teva Pharmaceutical Industries annual other non-cash items for 2023 were $0.902B, a 36.75% decline from 2022.
- Teva Pharmaceutical Industries annual other non-cash items for 2022 were $1.426B, a 100% increase from 2021.
Teva Pharmaceutical Industries Annual Other Non-Cash Items
(Millions of US $) |
| 2024 |
$2,582 |
| 2023 |
$902 |
| 2022 |
$1,426 |
| 2021 |
$713 |
| 2020 |
$5,946 |
| 2019 |
$922 |
| 2018 |
$4,899 |
| 2017 |
$18,207 |
| 2016 |
$2,171 |
| 2015 |
$1,670 |
| 2014 |
$287 |
| 2013 |
$-626 |
| 2012 |
$540 |
| 2011 |
$-297 |
| 2010 |
$25 |
| 2009 |
$16 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$19.207B |
$16.544B |
|
Teva Pharmaceutical Industries Limited is a global pharmaceutical company that develops, manufactures, and markets both branded and generic drugs, as well as active pharmaceutical ingredients in North America, Europe, Latin America, India, and Israel. Teva's generic product portfolio includes tablets, capsules, liquids, ointments, creams, liquids, injectables, and inhalants. The company's branded products include Copaxone, Austedo, respiratory products like ProAir and Qvar and Ajovy. Teva operates through three segments, North America, Europe and International Markets, each of which includes generics, specialty and over-the-counter products. Teva acquired Allergan's generics business Actavis Generics. The company also acquired Allergan's Anda Inc. Teva acquired Auspex Pharmaceuticals and Barr. Teva has strengthened its position in Europe through its acquisition of Germany's second largest generics producer, ratiopharm.
|
